SEC Form 4 · accession 0001209191-17-032899
ENDRA Life Sciences Inc. · NDRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David R. Wells
Officer — Chief Financial Officer
Period of report
May 12, 2017
Accepted (ET)
May 16, 2017 · 9:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001681682
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 12, 2017 | A | 18,833 | $0.00 | A | 18,833 | I | By StoryCorp Consulting |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF2 | $5.00 | May 12, 2017 | A | 15,000 | A | — | May 12, 2021 | Common Stock | 15,000 | 15,000 | D |
| Stock Options | $5.00 | May 12, 2017 | A | 7,000 | A | May 12, 2017 | May 12, 2022 | Common Stock | 7,000 | 7,000 | D |
Explanation of responses
- F1Award of restricted stock granted pursuant to the Issuer's 2016 Omnibus Incentive Plan.
- F2These Stock Options become exercisable in twelve equal quarterly installments beginning on August 12, 2017.